HomeProductsBioactive CompoundsJAK/STAT SignalingEGFRAllitinib
Chemical structure of CAS 897383-62-9

Allitinib

In Stock•Starting at $73 for 5 mg•Purity ≥ 99%
CAS No.897383-62-9
MDL No.MFCD17169993
MFC24H18ClFN4O2
MW448.90
InChI KeyMVZGYPSXNDCANY-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
5 mg99%$73In Stock
10 mg99%$108In Stock
50 mg99%$129In Stock
100 mg99%$216In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide is a quinazoline compound.

CAS No.897383-62-9
Product NameAllitinib

Biological Targets

EGFR·ERBB2

Associated Conditions

lung cancer
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Investigation of PM-induced carcinogenic effects through mediation of ErbB family based on DNA methylation and transcriptomics analysis by a lung-mimicking microfluidic platform.

Ecotoxicology and environmental safety • Vol. 248 • 2022
PMID: 36442402DOI: 10.1016/j.ecoenv.2022.114318

A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.

Journal of hematology & oncology • Vol. 7 • 2014
PMID: 24612546PMC: PMC4007625DOI: 10.1186/1756-8722-7-22

AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.

PloS one • Vol. 6, Issue 7 • 2011
PMID: 21789172PMC: PMC3138742DOI: 10.1371/journal.pone.0021487

Proceedings: Lorazepam in the treatment of neurosis--an uncontrolled clinical study.

Psychopharmacology bulletin • Vol. 12, Issue 1 • 1976
PMID: 1825

Documentation

Similar Products